Systemic sclerosis (SSc) is characterized by multi-organ
fibrosis with an autoimmune background. Although
autoantibodies are detected frequently in SSc patients, the role of
autoantibody in the development of
fibrosis remains unknown. Connective tissue homeostasis is a balance between the synthesis and degradation of the extracellular matrix (ECM); ECM degradation is regulated mainly by
matrix metalloproteinases (
MMPs). Anti-MMP-1 antibody is suggested to inhibit MMP-1 and be involved in the development of the
fibrosis in SSc. However, the accumulation of various ECM components in the tissue of SSc cannot be explained by the anti-MMP-1 antibody alone. In this study, we examined the presence or levels of antibody to MMP-3, a
protein which degrades various ECM components relevant to SSc
fibrosis.
Enzyme-linked
immunosorbent assay (ELISA) using human recombinant MMP-3 revealed that
IgG anti-MMP-3
autoantibody levels were elevated significantly in the sera from SSc patients, but not in patients with active
systemic lupus erythematosus or
dermatomyositis.
IgG and
IgM anti-MMP-3 antibody levels were significantly higher in diffuse cutaneous SSc, a severe form, than those in limited cutaneous SSc. Consistently,
IgG anti-MMP-3 antibody levels correlated significantly with
fibrosis of the skin, lung and renal blood vessels. The presence of
IgG anti-MMP-3
autoantibody in sera from SSc patients was confirmed by immunoblotting analysis. Remarkably, MMP-3 activity was inhibited by
IgG anti-MMP-3 antibody. These results suggest that anti-MMP-3 antibody is a serological marker that reflects the severity of SSc and also suggest that it may contribute to the development of
fibrosis by inhibiting MMP-3 activity and reducing the ECM turnover.